APP and Alzheimer disease: To further verify the effect of ALT001 on an AD mouse model, a 10-month-old PS2APP AD mouse model, double transgenic mice expressing mutant PS2 (PS2 N141I) and mutant APP (APP Swe), were also treated with ALT001 daily by intranasal administration (1 mg/kg) for 4 weeks, and cognitive function was assessed using the Morris water maze test.